These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 27865762)

  • 1. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
    Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
    Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging-assisted anticancer nanotherapy.
    Dasgupta A; Biancacci I; Kiessling F; Lammers T
    Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
    Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
    Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinspired approaches for cancer nanotheranostics.
    Evangelopoulos M; Tasciotti E
    Nanomedicine (Lond); 2017 Jan; 12(1):5-7. PubMed ID: 27876435
    [No Abstract]   [Full Text] [Related]  

  • 14. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocompatible polymersomes-based cancer theranostics: Towards multifunctional nanomedicine.
    Mohammadi M; Ramezani M; Abnous K; Alibolandi M
    Int J Pharm; 2017 Mar; 519(1-2):287-303. PubMed ID: 28115259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-targeted theranostic nanomedicines against cancer.
    Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
    J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity.
    Setia A; Challa RR; Vallamkonda B; Satti P; Mehata AK; Priya V; Kumar S; Muthu MS
    Nanotheranostics; 2024; 8(4):473-496. PubMed ID: 38961885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voyage of theranostic liposomes for imaging and therapy.
    Sachin M; Sachin D; Dinesh S
    J Cosmet Laser Ther; 2017 Aug; 19(4):245-249. PubMed ID: 28135901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic application of nanoemulsions in chemotherapy.
    Gorain B; Choudhury H; Nair AB; Dubey SK; Kesharwani P
    Drug Discov Today; 2020 Jul; 25(7):1174-1188. PubMed ID: 32344042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
    Jain V; Jain S; Mahajan SC
    Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.